


In the Claims

This listing of claims will replace all prior versions and listings of claims in this application.

1 (currently amended). A ~~compound method~~ for the treatment or prevention of a condition associated with T-cell proliferation or that is mediated by pro- and/or anti-inflammatory cytokines, wherein the ~~compound is said~~ method comprises administering, to a patient in need of such treatment, a compound of formula (I)



wherein R₁ is H or Me;

R₂ is H or alkyl and R₃ is H or Me, or R₂ and R₃ are -CH₂- thereby forming a ring;

n is 0 to 2;

X is CH₂ or O; and

the two benzene rings are each optionally substituted with OH, OMe, halogen, NHCHO, NHSO₂Me, CONH₂, SOMe, OCH₂O or CH₂OH;

and wherein the compound is selected from bufeniodc, denopamine, fenoterol, ifenprodil, isoxsuprine, labetalol, medroxalol, mesuprime, nylidrin, protokylol, ractopamine, ritodrine, salmefamol and sulfinalol.

2 (previously presented). The method according to claim 1, wherein the condition is a chronic degenerative disease such as rheumatoid arthritis, osteoarthritis or osteoporosis.

3 (previously presented). The method according to claim 1, wherein the condition is a chronic demyelinating disease such as multiple sclerosis.

4 (previously presented). The method according to claim 1, wherein the condition is a respiratory disease such as asthma or chronic obstructive pulmonary disease.

5 (previously presented). The method according to claim 1, wherein the condition is an inflammatory bowel disease (IBD) such as ulcerative colitis or Crohn's disease.

6 (previously presented). The method according to claim 1, wherein the condition is a dermatological condition such as psoriasis, scleroderma or atopic dermatitis.

7 (previously presented). The method according to claim 1, wherein the condition is a dental disease such as periodontal disease or gingivitis.

8 (previously presented). The method according to claim 1, wherein the condition is diabetic nephropathy, lupus nephritis, IgA nephropathy or glomerulonephritis.

9 (previously presented). The method according to claim 1, wherein the condition is systemic lupus erythematosus (SLE).

10 (previously presented). The method according to claim 1, wherein the condition is graft vs host disease.

11 (previously presented). The method according to claim 1, wherein the condition is a pain condition.

12 (previously presented). The method according to claim 11, wherein the pain condition is chronic pain such as chronic back pain, malignant pain, chronic headache (including migraine and cluster headaches) or arthritic pain.

13 (previously presented). The method according to claim 11, wherein the pain condition is acute pain such as post-operative pain, post-traumatic pain or acute disease-induced pain.

14 (previously presented). The method according to claim 11, wherein the pain condition is neuropathic pain.

15 (cancelled).

16 (currently amended). The method according to claim 1, wherein the compound is chiral and is in the form of the enantiomer or diastereomer that has relatively little or no activity at the α or β adrenoceptor.

17 (previously presented). The method according to claim 1, wherein the patient to be treated is also administered another therapeutic agent selected from corticosteroids, cytotoxics, antibiotics, immunosuppressants, non-steroidal anti-inflammatory drugs, narcotic analgesics, local anaesthetics, NMDA antagonists, neuroleptics, anti-convulsants, anti-spasmodics, anti-depressants and muscle relaxants.